Harmony Biosciences Holdings, Inc. ( NASDAQ: HRMY) Q1 2025 Earnings Call May 6, 2025 8:30 AM ET Brennan Doyle - Head, Investor Relations Jeffrey Dayno - President and Chief Executive Officer Adam ...

Cash flows have continued the positive trend in fourth quarter, reaching a total operating and investing cash flow of €91.1 million ... our balance sheet, we generated €50 million from ...

BridgeBio's valuation relies on the commercialization of Attruby, but the drug's full potential may be undermined by tafamidis’ patent extension, introduction of generic alternatives, and other ...

The medical technologies advisory committee considered evidence from several sources to determine whether price variation between slide sheets could be justified by differences in their clinical and ...

The future landscape of voice-based neurological assessment The field of vocal biomarkers for brain health continues to evolve rapidly, with several promising developments on the horizon.

Phase 2 data featured in an oral presentation at the American Academy of Neurology Annual Meeting ATH434-202 open-label trial in advanced MSA completed in March 2025 Cash balance on 31 March 2025 of ...

today released its Appendix 4C Quarterly Cash Flow Report and update on company activities for the quarter ending 31 March 2025 (Q3 FY25). David Stamler, M.D., Chief Executive Officer of Alterity, ...

Consolidated Revenues of $2.26 billion, up 5% on a Reported basis and 6% on an Organic (non-GAAP) 1 basis over the prior year periodGAAP Net Loss Attributable to Bausch Health Companies of $58 million ...

Delivered high-single-digit revenue growth, double-digit organic revenue growth, and continued operating margin expansion Raised full-year 2025 revenue guidance; updated full-year 2025 guidance ...

Consolidated Revenues of $2.26 billion, up 5% on a Reported basis and 6% on an Organic (non-GAAP) 1 basis over the prior year periodGAAP Net Loss Attributable to Bausch Health Companies of ...